Kapstone Financial Advisors’s Pfizer PFE Stock Holding History

Kapstone Financial Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,266	Closed	-$229K	–	113
2024 Q1	$229K	Sell	8,266 -1,583	-16%	-$43.9K	0.16%	93
2023 Q4	$271K	Sell	9,849 -2,182	-18%	-$66K	0.21%	85
2023 Q3	$399K	Buy	12,031 +139	+1%	+$4.92K	0.36%	55
2023 Q2	$423K	Buy	11,892 +1,441	+14%	+$56.1K	0.35%	58
2023 Q1	$433K	Buy	10,451 +647	+7%	+$27.9K	0.39%	56
2022 Q4	$435K	Buy	+9,804	New	+$470K	0.4%	56

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kapstone Financial Advisors's PFE Position: Q2 2024 in Review

Kapstone Financial Advisors sold out of Pfizer (PFE) in Q2 2024, closing a stake of 8,266 shares — an estimated $229K sold.

Kapstone Financial Advisors first reported a position in PFE in Q4 2022 and held it in 6 quarters. The position peaked at $435K in Q4 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Kapstone Financial Advisors reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Kapstone Financial Advisors sold 8,266 Pfizer shares in Q2 2024, an estimated $229K.
Kapstone Financial Advisors first reported a position in Pfizer in Q4 2022 and held it in 6 quarters.
Kapstone Financial Advisors's Pfizer position peaked at $435K in Q4 2022.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Kapstone Financial Advisors's 13F filing for Q2 2024, filed 2 Aug 2024.